Article

The Exploratory Research of NSCLC with Concomitant EGFR Mutations and ALK Rearrangements

2020-12-28

Abstract excerpt

<title>Abstract</title> <p><bold>Background</bold>: Epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangements are two driver alterations and are generally considered mutually exclusive in non-small cell lung cancer (NSCLC). The prevalence of EGFR/ALK co-alterations in patients with NSCLC is low, and the clinicopathological features and optimal targeted therapies of thes...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 19f8ce18-8f5d-5ec2-81da-f154cc960f21
DOI: 10.21203/rs.3.rs-130711/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

The Exploratory Research of NSCLC with Concomitant EGFR Mutations and ALK RearrangementsDOI 10.21203/rs.3.rs-130711/v1Read

[Advances in Double Mutations of EGFR and ALK Gene in Non-small Cell Lung Cancer].Semantic proximity Read

Clinical outcomes of advanced non-small-cell lung cancer patients with EGFR mutation, ALK rearrangement and EGFR/ALK co-alterations.Semantic proximity Read

Genetic and treatment profiles of patients with concurrent Epidermal Growth Factor Receptor (EGFR) and Anaplastic Lymphoma Kinase (ALK) mutations.Semantic proximity Read

Concurrent driver mutations/rearrangements in non-small-cell lung cancer.Semantic proximity Read

Oncogenic Fusions in NSCLC: From Mechanisms to Clinical ApplicationsSemantic proximity Read

Concomitant EGFR mutation and ALK rearrangement in lung adenocarcinoma is more frequent than expected: report of a case and review of the literature with demonstration of genes alteration into the same tumor cells.Semantic proximity Read

Real-World Efficacy of First- and Second-Generation EGFR TKIs in NSCLC with EGFR Co-mutations: A Vietnamese Cohort StudySemantic proximity Read

Clinical Outcome of ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs).Semantic proximity Read

ALK alterations and inhibition in lung cancer.Semantic proximity Read

Concomitant driver mutations in advanced EGFR -mutated non-small-cell lung cancer and their impact on erlotinib treatmentSemantic proximity Read

Therapeutic Advances of Rare ALK Fusions in Non-Small Cell Lung CancerSemantic proximity Read

Clinical difference on the variants and co-mutation in a Chinese cohort with ALK-positive advanced non-small cell lung cancer.Semantic proximity Read